跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CLEC-1
首页
药物
CLEC-1
CLEC-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
HETERODIMERIC FC-CLEC-1 FUSION MOLECULE AND USES THEREOF
US 20260035434 A1
申请人: OSE IMMUNOTHERAPEUTICS
优先权: 2022
CN
EP
US
WO
4 件公开
MOUSE ANTI-AGGRUS MONOCLONAL ANTIBODIES
US 2014235827 A1
申请人: FUJITA NAOYA
优先权: 2011
CN
US
3 件公开
Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)
US 11365257 B2
申请人: INST NAT SANTE RECH MED
优先权: 2016
CN
US
3 件公开
Identification of CLEC-1 Ligand and Uses Thereof
US 20250026839 A1
申请人: OSE IMMUNOTHERAPEUTICS
优先权: 2021
CN
US
2 件公开
Vinylene carbonate preparation method
CN 104327037 A
申请人: QING MU HIGH TECH MATERIALS CO LTD
优先权: 2014
CN
Method for co-production of chloro ethylene carbonate and bio-based plasticizer
CN 115677646 A
申请人: FUJIAN ZHISHANG BIOMASS MAT CO LTD
优先权: 2022
CN
IDENTIFICATION OF HLA-DRA AS A LIGAND OF CLEC-1 AND USES THEREOF
WO 2025032213 A1
申请人: OSE IMMUNOTHERAPEUTICS
优先权: 2023
WO
药物
反馈